多发性硬化疾病修饰治疗与非感染性葡萄膜炎风险
这项回顾性队列研究利用Optum数据库2000至2022年医疗索赔数据,纳入43,501例成人多发性硬化患者共48,221个治疗 episode,比较不同疾病修饰治疗(DMT)与非感染性葡萄膜炎(NIU)发生风险的关系。以醋酸格拉替雷为参照,核酸合成抑制剂/S1P调节剂、富马酸类、抗CD20单抗和干扰素与较低的NIU风险相关,而那他珠单抗未见显著差异。
要点
- 以醋酸格拉替雷为参照,核酸合成抑制剂/S1P调节剂与NIU风险降低相关(aHR 0.14)。
- 富马酸类、抗CD20单抗和干扰素亦与较低的NIU风险相关,那他珠单抗无显著差异。
- 敏感性分析支持富马酸类和核酸合成抑制剂/S1P调节剂的保护性关联。
核心结论
- 某些DMT类别与多发性硬化患者非感染性葡萄膜炎风险降低相关,若被证实可用于个体化治疗并可能拓展至其他人群的NIU治疗。
研究设计与样本
- 回顾性临床队列研究,使用Optum去标识化Clinformatics Data Mart数据库2000年1月1日至2022年6月30日的商业和Medicare Advantage保险索赔数据。
- 纳入≥3个不同日期诊断码定义的多发性硬化成人,接受≥1种DMT处方且既往入组≥2年,共48,221个治疗 episode(43,501例患者),允许换药后多次贡献。
主要发现
- 中位随访562至703天,以醋酸格拉替雷为参照,NIU发生率较低见于核酸合成抑制剂/S1P调节剂(aHR 0.14,95%CI 0.07-0.29)、富马酸类(aHR 0.51,95%CI 0.36-0.74)、抗CD20(aHR 0.66,95%CI 0.51-0.85)和干扰素(aHR 0.67,95%CI 0.50-0.91)。
- 那他珠单抗与NIU风险无显著关联(aHR 0.87,95%CI 0.61-1.24)。
- 敏感性分析证实富马酸类(aHR 0.56,95%CI 0.38-0.82)和核酸合成抑制剂/S1P调节剂(aHR 0.16,95%CI 0.08-0.33)的关联。
关键数值与推荐
- NIU定义为新的国际疾病分类码且120天内第二次确认诊断;敏感性分析要求诊断120天内新开具糖皮质激素处方或眼部注射。
- 采用边际Cox模型与稳健三明治协方差估计计算调整风险比(aHR),并使用DMT特异性倾向评分模型的重叠权重调整。
临床怎么用
- 在多发性硬化患者的DMT选择中,可考虑不同药物对非感染性葡萄膜炎风险的潜在差异,尤其对已有葡萄膜炎风险担忧者。
局限性
- 回顾性索赔数据库研究可能存在编码误分类和未测量混杂,结果需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Multiple sclerosis (MS) is associated with an increased risk of noninfectious uveitis (NIU). Whether disease-modifying therapies (DMTs) for MS alter this risk is unknown. Our objective was to determine the comparative risk of NIU after DMT initiation for MS. DESIGN: Retrospective clinical cohort study using Optum's deidentified Clinformatics Data Mart database, which is comprised of medical claims for patients enrolled in commercial and Medicare Advantage insurance plans from January 1, 2000, to June 30, 2022. PARTICIPANTS: Adults with MS, defined by ≥3 diagnosis codes on separate dates, who received ≥1 DMT prescription and had ≥2 years of prior enrollment. Participants could contribute multiple treatment episodes if they switched therapies. METHODS: Users of interferons, fumarates, nucleic acid synthesis inhibitors/sphingosine-1-phosphate (S1P) modulators, natalizumab, and anti-CD20 monoclonal antibodies were compared to glatiramer acetate as the reference. MAIN OUTCOME MEASURES: Marginal Cox models with robust sandwich covariance matrix estimation were used to calculate adjusted hazard ratios (aHR) for incident NIU, defined as a new International Classification of Diseases code for NIU with a 2nd confirmatory diagnosis within 120 days. A sensitivity analysis varied this definition to require a new concurrent corticosteroid prescription or ocular injection within 120 days of diagnosis. DMT-specific propensity score models were constructed using multivariable logistic regression with generalized estimating equations to calculate overlap weights for adjustment. Participants were censored if they switched treatments, underwent intraocular surgery, or disenrolled. RESULTS: Across 48,221 treatment episodes for 43,501 patients, median follow-up ranged from 562 to 703 days. Compared to glatiramer acetate, the NIU incidence was lower for nucleic acid synthesis inhibitors/S1P modulators (aHR 0.14, 95% CI: 0.07-0.29), fumarates (aHR 0.51, 95% CI: 0.36-0.74), anti-CD20 (aHR 0.66, 95% CI, 0.51-0.85), and interferons (aHR 0.67, 95% CI: 0.50-0.91), but not natalizumab (aHR 0.87, 95% CI: 0.61-1.24). Sensitivity analysis confirmed findings for fumarates (aHR 0.56, 95% CI: 0.38-0.82) and nucleic acid synthesis inhibitors/S1P modulators (aHR 0.16, 95% CI: 0.08-0.33). CONCLUSIONS: Certain DMT classes are associated with a protective effect for NIU in MS. If confirmed, these medications could be targeted for personalized MS treatment and potentially repurposed to treat NIU in other patient populations.
引用
- Cordisco AJ, Jin F, Hamedani AG, et al. Risk of Noninfectious Uveitis Associated With Disease-Modifying Therapies for Multiple Sclerosis. Am J Ophthalmol. 2026. PMID: 42097475. doi:10.1016/j.ajo.2026.04.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。